AATec Medical GmbH

Established in 2021 and based in Munich, Germany, AATec Medical GmbH operates as a biotech company that provides a product platform for the treatment of inflammatory disorders. Rüdiger Jankowsky (CEO), Manfred Stangl (CSO), Michael Strassmair (CMO), Karsten Ottenberg, and Willem Bulthuis are the co-founders of the company. In July 2023, AATec Medical GmbH raised EUR 2. 7 million in Seed funding from investors.

The company provides Alpha-1 antitrypsin (AAT), which is a human serine protease inhibitor essential for protecting tissues from damage caused by proteases while also possessing immunomodulatory functions and providing broad antiviral therapeutic effects. The firm’s product candidate, ATL-105, which is an AAT formulation for inhalation used to treat developing inflammatory disorders of the lung and respiratory virus infections. The company's drugs are made from human plasma and use protein formulation technology combined with cutting-edge inhalation technology to deliver therapeutic proteins directly to the respiratory system. AAT products are used in the treatment of AAT deficiency, a severe genetic condition.

AATec Medical is also developing AAT products for inflammatory diseases, respiratory virus infections, and various other diseases and handheld inhalers to enable broad use of their treatments. The startup’s partners include Ludwig-Maximilians-University of Munich, University of Ulm, Helmholtz Zentrum München, and Goethe University Frankfurt am Main. The organization plans to use the July 2023 funding to expand its team, develop its technology, and prepare for clinical studies.